The activation and disruption of platelets resulting from contact with bypass equip ment is responsible for bleeding problems after open-heart surgery and for vascular injury leading to cerebral damage. This paper presents experimental and clinical evidence for the benefits of the preservation of platelets by prostacyclin (PGI2) during cardiopulmonary bypass operations.
Introduction
The discovery of prostacyclin (PGI2) in 1976 (see , the most powerful inhibitor of platelet function described so far, was of immediate interest to those of us who are concerned about the unsatisfactory results of contemporary cardiopulmonary bypass pro cedures. Many of the problems after open-heart surgery are attributable to deficiencies of the haemostatic system. Post-operative bleeding, embolism and thrombosis are occasionally a threat to life and very commonly a cause of post-operative morbidity. Heparin anticoagulation and protamine reversal is still the only technique available for routine use in open-heart surgery. For many years this combination has been recognized as less than satisfactory (Bass & Longmore 1969; Aberg 1974) .
The adverse effects of protamine, a family of basic polypeptides, are well known (Larkin et al. 1978; Ellison et al. 1978; Velders 1980) . The use of heparin, a family of complex poly saccharides, while preventing gross coagulation of blood, does not inhibit the first stages of the clotting cascade. Platelets are activated and destroyed as a result of the contact between blood and the artificial surfaces of the heart-lung machine. Heparin may itself exacerbate such destruction (Wolf 1967) .
After open-heart surgery, the patient's recovery is always very much slower than after closed-heart or general surgery. Post-operative complications include varying degrees of psycho-pathological disturbances. Some patients are unable to work or live in harmony with their families after contemporary open-heart surgery. Surgical life-saving triumphs are all too commonly marred by disabling complications. These complications are more serious than might be expected from the loss of some platelets. Platelet adhesion to the extracorporeal apparatus and aggregation, not prevented by heparin, leads to the release of platelet granular constituents. ADP, 5-hydroxytryptamine and the small proteins p-thromboglobulin ( 0TG) and platelet factor 4 (PF4) are released into the circulation.
Some of the released substances are procoagulant (Broekman 1975) 5 and when caused by abnormal platelet activation may seriously disturb the chemical balance regulating normal endothelial repair in haemostasis. There is evidence supporting the theory that the heparin neutralizing activity present in blood is due to PF4 released from platelets (Niewiarowski 1976) . pTG is a significant component of this protein secretion and may inhibit local production of PGI2 (Hope et al. 1979) .
During cardiopulmonary bypass, haemodiluting fluids used in the prime and administered to the patient pass rapidly into the extravascular space, suggesting to us that there is increased capillary permeability. We do not know whether this is related to release of 5-hydroxytrypt amine and other substances from adherent and disrupting platelets.
D og experiments
We set out in 1978 to establish in the dog whether the use of PGI2 would eliminate anticoagulant-related complications of bypass. Initially we undertook three series of experiments (Longmore et al. 1979) , using PGI2 alone, a control group with heparin alone and a series with routine heparinization together with PGI2.
In all three sets of experiments similar anaesthetic and surgical techniques were used. A simple bypass circuit was used with gravity drainage from an 8 mm atrial basket to a Bentley paediatric QUO bubble oxygenator. This was connected to a single-roller pulsatile arterial pump with a finely adjustable driven roller to avoid trauma to the blood. A special feature of the bypass circuit was the inclusion of two filters in series in the arterial line. Pressure take-off points proximal to the first filter, between the filters, and distal to the second filter were used to detect clogging of the filters. Scanning electron microscopy of both sides of both filters was used to determine whether material found on the filter surfaces was deposited on or generated by the filters.
Bypass with PGI2 alone
With the use of the circuit described above, PGI2 alone was used for 1 h bypass in 14 beagles. Remarkably, we achieved long-term survival in all but the first in which there was a technical failure unrelated to the use of PGI2. During the surgery in this group, the wounds were dry, appearing as they are in conventional operations performed without extracorporeal circulation and heparinization. There was no measurable blood loss during or after the surgery. Never theless, the plasma fibrinogen was reduced and there was frank clot in those regions of the extracorporeal circulation in which there was stasis. There were clots on both filters.
At this stage of the development of oxygenators, reservoirs and filters, the designs for heat exchange and debubbling depend on blood standing in contact with heat exchange surfaces and in holding areas. Until a new generation of apparatus, already designed on different principles, becomes acceptable it will probably not be possible to use PGI2 on its own. pgi2 and cardiopulmonary bypass 401 
Heparin alone
We undertook two further sets of experiments on greyhounds. In the first six control experi ments the dogs were given heparin 300 i.u./kg intravenously (i.v.) 5 min before starting a 2 h bypass.
Heparin plus PGI2
A further eight experiments were undertaken by using the same heparin routine and prosta cyclin at 10 ng kg-1 min-1 i.v. for 15 min before bypass and then 1 |ig kg-1 min-1 into the venous return line near to the heart so that the PGI2 was in maximum concentration in the oxygenator for the 2 h of bypass. All dogs were given protamine sulphate in a 1:1 ratio to the total heparin dose at the end of bypass.
Blood samples were taken after induction of anaesthesia, when the PGI2 infusion was started, at the beginning of bypass, every 15 min during and after bypass, and after protamine admini stration until recovery. These samples were used for haemotocrit determination, platelet counts (phase contrast microscopy), and testing on foetal hearts. Platelet-rich plasma was obtained by centrifugation of citrated blood at 1000 g. Aggregation was induced by adenosine diphosphate (20-100 pmol/1) and measured as the increase in light transmission over 2 min in a Born-type aggregometer (Payton dual-channel). Total clotting fibrinogen, thrombin-clotting time, as well as the above measurements, were estimated at the same times and 24 h after operation.
Filters were rapidly removed after bypass and fixed for scanning electron microscopy. During the bypass and during wound closure any bleeding was noted. The pressure differential across the two filters in the arterial line was recorded every 5 min during bypass.
To study possible changes in the plasma proteins and any toxic substances that might be released from damaged platelets, foetal mouse hearts in organ culture were used (Wildenthal 1970 , 1971a , b\ Hughes & Longmore 1972 Longmore & Smith 1980) . Foetal hearts were taken from Theier's (T.O.) pure-strain mice that had been mated 15 days previously; 15 control and 15 test hearts were each cultured in 2 ml o f'Wellcome' 199 culture medium and 1 ml of plasma with cortisol (1 |ig/ml) and insulin (50 pg/ml). The plasma was obtained from samples of blood drawn from the oxygenator just before the end of bypass. The hearts were cultured in 95 % Oa and 5% C0 2 at 37 °C. They were examined under a dissecting microscope every 24 h and returned to the incubator when the beating rate had been recorded.
Results of preliminary dog experiments
The results of the dog experiments were unequivocal. In the series with heparin only the wounds remained wet throughout the operation. There was some post-operative oozing from the chest wound. All the dogs recovered slowly. One died 6 h post-operatively of haemorrhage. Two more died within 24 h. The platelet count, corrected for haemodilution (figure 1), fell to below 50 % during the bypass and even further to 35 % after protamine was given. The few platelets remaining in the circulating blood after the protamine injection were incapable of aggregation (figure 2). The plasma fibrinogen was reduced. The pressure differential across the filters in three of the dogs showed a fluctuating pattern: building up, falling, and then building up again.
In the protein-denaturation studies on mouse foetal hearts, there was a significant depression of beating-rate and reduction of survival time (compared with the control plasmas) in hearts re ceiving plasma from dogs bypassed with heparin alone (figure 3). Scanning electron microscopy [ 185 ] scopy showed a build-up of platelet aggregates on both sides of both filters. The platelets cover ing the surfaces were breaking down and fibrin strands were forming with red and white cells enmeshed (figure 4 a,plate 1). In contrast, in the series combining heparin and PGI2, there was no fall in platelet count, no change in platelet activity, and no fall in plasma fibrinogen. Furthermore, there was no increase protamine protamine F ig u r e 1. Platelet counts during 2 h bypass operations on dogs with heparin alone (o), PGI2 alone ( a ) and a combination of the two (•). A.p., after protamine.
time on bypass/min Aggregability of dog platelets to ADP during bypass with heparin alone (o) and with heparin plus PG12 (•). The ability of platelets to aggregate after a conventional bypass is about 10 % of control. This was improved to over 80% with heparin and PGI2. A.p., after protamine.
in pressure across the filters during the 2 h of bypass. Platelet aggregation returned to normal wtthm 30 mm of the end of prostacyclin infusion. Electron microscopy showed that the filter mesh had only a few adhering platelets. The platelets that had adhered did not appear to have broken down. There were no fibrin strands formed (figure 44). Plasma taken at the end of bypass from these dogs had no significant effect on the beating rate and survival time of the foetal hearts.
Phil. Trans. R. Soc. Lond. volume 294 Longmore, plate 1 F ig u r e 4. (a) Scanning electron microscopy showed a build-up of platelet aggregates, fibrin strands and red and white cells on the filter from the bypass with heparin alone. ( Scanning electron microscopy showed few platelet aggregates and no fibrin strands when PGI2 was used in combination with heparin. (Facing 403) on October 27, 2017 http://rstb.royalsocietypublishing.org/ Downloaded from pgi2 and cardiopulmonary bypass 403 The advantageous effects of prostacyclin in the experiments were not accompanied by any apparent disadvantages. The remarkably low mortality rate in the PGI2 dog series strongly suggested that the use of PGI2 in human bypass would be safe. It is well known that the dog is less able than man to withstand the trauma of cardiopulmonary bypass.
bypass plasma sample:
F ig u r e 3. Influence of dog plasma on heart rate and survival time of cultured foetal mouse hearts, showing the reduction of these by plasma from the ' heparin only ' group. This difference was not seen in the presence of p g i 2.
T he clinical trial
Encouraged by the positive results obtained in the dog laboratory, we undertook a double blind trial in man, by using PGI2 in combination with routine heparinization (Longmore et al. 1981) . This trial was designed to establish whether the beneficial effects of PGI2 seen in the dog would translate to the human. In addition we also set out to establish whether there would be any measurable clinical benefits from the improved haematological picture obtained when PGI2 was used. We concentrated on post-operative bleeding and multi-organ damage in cluding brain damage.
Patients and clinical aspects
The study was carried out on 24 male patients between ages of 36 and 64 years (mean 52 years) in which 12 received PGI2 and 12 received placebo. One patient (subsequently found to be receiving placebo) was excluded from this study because he had to be returned to theatre with cardiac tamponade. Patients undergoing coronary vein grafts were chosen because they are a homogeneous group operated on with a closed heart. The operating techniques used utilise minimal suction and cause minimal tissue damage. Thus, as in the preliminary study on dogs, most activation of platelets would be due to the traumatic passage of blood through the extracorporeal apparatus. The patients were operated on by Mr Donald Ross, Mr Magdi Yacoub and Mr Graeme Bennett at the National Heart Hospital, using similar techniques. A common anaesthetic protocol was used in every case.
In all the patients a routine bypass circuit with a Bos 10 Bentley oxygenator and Sarn's pumps
was primed with 2 1 of Hartmann's solution and 3000 i.u. heparin added. Flow rates varied between 2.2 and 2.4 1 m2 min-1. Three suckers were available for the surgeons. These discharged into a Bentley cardiotomy reservoir with a 40 pm in-line filter. No arterial line filtration was used. PGI2 (synthesized by Upjohn Co. and formulated by the Wellcome Foundation Ltd), reconstituted from the freeze-dried sodium salt (0.5 mg) in glycine buffer (pH 10.5, Wellcome Foundation Ltd) and diluted to the required concentration in normal sterile saline (or placebo (Wellcome Foundation Ltd) containing all ingredients except active drug), was infused by a peristaltic Tekmar drip pump through a central venous line. Infusion of PGI2 or placebo was started after induction of anaesthesia at a dose rate of 10 ng kg-1 min-1 and increased to 20 ng kg-1 min-1 at the beginning of bypass. Heparin was given routinely (9000 i.u./m 2 body surface area) after saphenous vein mobilization was completed, and haemostasis was obtained before cannulation of the great vessels. Heparinization was monitored throughout by measuring activated clotting time by means of a Hemochron instrument (International Technidyne Corporation). Reinforcing doses of heparin were given when the Hemochron time fell below 350 s. The PGI2 or placebo infusion was stopped at the end of bypass and protamine given in a 1:1 ratio to the total heparin dose. Blood and perfusion pressures were recorded continuously and any facial flushing or other unusual features noted. Blood given, blood loss, urine output and fluid given were also recorded before, during and after bypass. Every 30 min on bypass 7. At the end of bypass before cardioactive drugs are administered (foetal heart test only) 8. 15 min after protamine administration .9 2 h after bypass 10. 6 h after bypass (CK and BTG assays only) 11. 24 h after bypass 12. 3 days after bypass (CK and BTG assays and psychometric testing). 13. 6 days after bypass (psychometric and neurological tests)
Haematological and biochemical tests
Blood samples were taken from the radial arterial line or, during bypass, from the arterial reservoir of the pump circuit via a fine catheter.
Sampling times covered the period from induction of anaesthesia to the day after surgery (table 1). Samples were taken at times 2, 3, 4, 6 a, 6 b, 6 c, 8, 9, 10 and 11 for the following haematological tests: haematocrit, haemoglobin, white blood cell count, platelet count, plate let aggregation, prothrombin time, thrombin time, partial thromboplastin time, fibrinogen, anti-thrombin III, and (3-thromboglobulin.
(3-Thromboglobulin levels were measured by radioimmunoassay with the double antibody (Ludlaim et al. 1975) .
In addition to these investigations, creatine kinase (including MB isoenzymes) levels were also measured at times 9, 10, 11 and 12. p g i 2 a n d c a r d i o p u l m o n a r y b y p a s s 405 Post-operative urine samples were collected for creatinine clearance studies. The urine samples were divided into three to avoid loss through accidental spillage or nurses discarding the samples. Platelet aggregability was measured by the Born (1962) technique with a Payton aggregometer. The latter was measured in platelet-rich plasma within 2 min of the blood sample being withdrawn. The degree of aggregability was related to the maximum aggregation attainable with ADP in each specimen. 6a 6 b sample no. The foetal heart test was used as in the dog experiments on samples taken at times 5 and 7. Psychometric testing was undertaken at times 1, 12 and 13. These tests are designed to detect any post-operative cerebral dysfunction. The testing plan at each testing time (Bethune 1980 ) included short-term memory recall, the 'Tooting Bee' questionnaire, a digital test, a number connection test and questions relating to the distant past. The complete test takes 20-25 min. At sample times 1 and 13, a routine clinical neurological examination with the use of a fixed proto col, including assessment of cranial nerve function, cerebellar function, muscle power, reflexes and coordination, was undertaken.
after bypass. This indication of dilution can be used to apply a correction factor to other measurements such as platelet counts.
There was no significant difference between the control and test group for prothrombin time, partial thromboplastin time, fibrinogen, antithrombin III, creatine kinase and CK and MB isoenzymes, and P-thromboglobulin. sample no.
F ig u r e 6. The variation of Hemochron value ( a) and thrombin time w Both variables were lower in the placebo group throughout bypass in spite of the higher dosage of heparin required by these patients. *, p < 0.01; **, p < 0.05; bars indicate stan
In the PGI2 group the Hemochron times varied between 400 and 800 s during bypass. The patients receiving heparin alone showed a very significant lower Hemochron time (p < 0.01 in early bypass; figure 6). Some of the placebo group of patients fell below 400 s towards the end of bypass and required an extra reinforcing dose of heparin with a correspondingly increased dose of protamine.
The thrombin times were slightly raised in the PGI2 group from the time of administration of the heparin dose until 6 h after bypass, when they became the same as in the heparin group.
Platelet counts were consistently higher throughout bypass in the PGI2 patients than in the placebo group (p < 0.01). Figure 7 relates the platelet count and the platelet aggregation.
Platelet aggregation was reduced to 20 % of initial values by PGI2 throughout the period of its administration. In the prostacyclin group the platelet aggregation had recovered to 70 % of the initial value 2 h after bypass. In the placebo group, platelet aggregability decreased gradually during bypass to approximately 30 % of initial values and only partly recovered 2 h after bypass. By 24 h after bypass there was no significant difference. [ 190 ] F ig u r e 7. Variation of platelet count (a) and platelet aggregability (b) to ADP with (-----) and without (-----) PGI2. Note the protection of the platelet population in the presence of PGI2, and also that their aggregability is markedly diminished during bypass, recovering to ca. 70 % 6 h later, whereas in the placebo group it is only 45% at this critical post-operative time. 
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Clinical measurements
The clinical measurements are summarized in table 2. As expected, prostacyclin induced some hypotension, but this caused no difficulties in the clinical management of the patients. Only two patients required small doses of vasopressors. Our protocol allowed for any fall in blood pressure to be treated by the administration of additional fluid. In fact less fluid was required by the PGI2 group. In spite of the lower blood pressures before bypass in the PGI2 groups, the urine outputs were not significantly different in the two groups.
survival time/days F igure 8. Reduction of heart rate and survival time (a) of cultured foetal mouse hearts; ( linear regression analysis. The hearts exposed to plasma from the placebo group (a ) show a significant depression of beating rate and survival time compared with that from a normal control (o) and the PGI2 group (a). **,p < 0.05; ***, p < 0.001.
We were unable to detect significant differences in the cerebral function and neurological status between the two groups of patients. No patient in either group showed any permanent detectable psychopathological change. All became more skilful with the repeated tests, showing an apparent improvement by 6 days after operation. Importantly, over half of the placebo group complained of inability to focus their eyes and to read newspaper print for 48 h. None of the PGI2 group suffered from this disability.
The foetal heart culture test showed a significant depression of the foetal hearts exposed to plasma taken from blood samples no. 7 at the end of bypass in the placebo group, with reduction of the beating rate and survival time (p < 0.001) as shown in figure 8. Median survival times (l.t.50) showed no significant difference between the foetal hearts exposed to plasma proteins from the PGI2 group and plasma obtained from a normal volunteer, whereas there were marked differences with the placebo sample. The creatinine clearance test showed no significant difference between the two groups.
D iscussion
The three known effects of prostacyclin were confirmed with this study: stabilization of the platelet in the extracorporeal circulation, the heparin sparing effect and the vasodilator effect. In addition to these effects of PGI2, our studies suggest that PGI2 reduces the capillary damage leading to increased capillary permeability that takes place during cardiopulmonary bypass. The mechanism of this may be related to the reduction of platelet granule release. This mecha nism is suggested by the foetal heart studies.
Foetal heart test
The foetal hearts showed significantly better survival times and beating performance when exposed to plasma from patients who had received PGI2 compared with those who had re ceived placebo. This is probably due to a reduction in the amount of platelet granular sub stances liberated when prostacyclin is administered. In our previous studies without the use of PGI2 (Longmore etal. 1980) we have always shown depression of beating rate and survival time in foetal hearts when they are exposed to plasma taken at the end of bypass. The corresponding plasma from the PGI2 patients was comparable with the control blood drawn from the healthy volunteer. It has been argued that the cause of the depression of the foetal hearts that follows a normal bypass may be associated with mechanical damage to proteins or may be due to protein damage following granule release from platelets. The beneficial effects of PGI2 suggests the latter mechanism, as does the possible change in capillary permeability.
The P-thromboglobulin results do not help to resolve this problem. Plasma P-thromboglobulin concentration was increased in samples from both groups during and after surgery. This suggests a high level of platelet activation, but massive vitro liberation of pTG may take place in the long cannulae through which blood samples were withdrawn.
Platelet aggregation and reduction of blood loss
The PGI2 effect on platelet aggregation in the human clinical trial was less profound than in the experiments on dogs. Nevertheless, there was virtually complete preservation of the platelet population throughout cardiopulmonary bypass. Importantly, the platelet function returned almost to normal after bypass with a concomitant halving of blood loss. No patient in the PGI2 series bled sufficiently to cause anxiety post-operatively. The total blood loss was so small that administration of blood after bypass would appear to be superfluous when PGI2 is used.
Heparin sparing effect
The heparin sparing effect previously described in experimental renal dialysis by Woods et al. (1978) was confirmed. The effect of this was to reduce the amount of additional heparin required towards the end of bypass to maintain an acceptable Hemochron level. The amount of protamine required in the PGI2 group was correspondingly less.
The vasodilator effect of PGI2
The vasodilator effect of the pre-perfusion dose of 10 ng kg-1 min-1 was variable. It was troublesome enough to indicate the need for small doses of vasopressor agents in only two patients. In all other cases in this series, the anaesthetist was unable to determine whether prostacyclin was present although he was looking for hypotension and facial flushing. We expected that the hypotensive effects of PGI2 might require the administration of more fluids during bypass to maintain the blood pressure; even when the dose of PGI2 was doubled to 20 ng kg-1 min-1 at the beginning of bypass this was not so. There was no significant difference between the flow rates in the two groups, although it is our practice to increase the flow rather than administer vasopressors when the perfusion pressures are low.
We also considered the theoretical possibility that any hypotension before the bypass started could cause a reduction in renal perfusion and urine flow. If this was followed by an increase in urine flow towards the end of bypass, it might be difficult to administer sufficient potassium in the depleted patient. We did not experience this problem. In two patients in the PGI2 group, the urine flow was reduced before bypass, but within the first few minutes of bypass, urine started to flow. No difficulties in the management of the serum potassium was experienced in these patients.
In this series, Bos 10 bubble oxygenators were used because we were not certain what the effects of PGI2 would be on the deposition of the layer of blood products on the surface of 'Celgard' microporous membranes upon which oxygenation depends in some membrane oxygenators. In a subsequent pilot study of membrane oxygenators, using dogs, we find by scanning electron micrography that in spite of the presence of prostacyclin, this essential layer is deposited although it is thinner. There would appear to be no contra-indication to the use of PGI2 with membrane oxygenators. We are investigating this further.
We were disappointed that the reduction in the amount of brain damage that sometimes occurs in cardiopulmonary bypass owing to platelet aggregates and intravascular clotting was not obvious in this trial. We used the memory recall tests devised by Bethune (1980) . In all our patients, 3 days after operation there was a demonstrable impairment of cerebral function, but by 6 days after operation no patient showed any cerebral dysfunction according to the test. Bethune now feels that the test is not sufficiently sensitive for this purpose. The International Group (Katz etal. 1978 ) studying cerebral damage after open-heart surgery is proposing to combination of memory recall, conceptual logic analogue testing and word rotation tests; this is more sensitive. We obtained some difficulty in obtaining the patients' attention in the busy pre operative period and feel that a long and complex test is undesirable and might distress the patient at that time. Over half of the placebo patients complained of visual disturbances that were not experienced by the PGI2 group. Further investigation is required to find whether PGI2 will eliminate all multi-organ and cerebral complications.
C onclusion
In spite of the theoretical possible disadvantages of the vasodilator effects of PGI2 referred to by Salzman (this symposium), both animal studies and a carefully conducted double-blind human clinical trial show them to be irrelevant and far outweighed by the real measured advantages of its use.
Exploitation of the beneficial effects of PGI2 in extracorporeal circulation probably presents the most important potential advance in open-heart surgery in the 23 years since it first became routine.
There are, however, two coincidental advances, which probably make the discovery of PGI2 even more important. These are in the unrelated field of computer-enhanced non-invasive instruments for the early diagnosis of cardiovascular disease (Longmore 1976 ) and the [ 194 ] discovery of growth-limiting substances of the arterial wall smooth muscle cells (Florentin J973 5 Nam et al. 1974; Thomas et al. 1976) . We may soon enter a new era in the management of cardiovascular disease, with early diagnosis of atherosclerosis, inhibition of untoward platelet activity blocking vessels and stimulating smooth muscle proliferation (Stemerman 1979) , and control of hyperplastic smooth muscle. PGI2 is an important first member of a family of sub stances that may well enable medicine to influence the progress of the disease process which causes over half of all deaths and morbidity in the Western World.
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